Overview

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2034-03-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Phase:

PHASE2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

BioNTech SE

Treatments:

Bevacizumab
Folfox protocol
IFL protocol